Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-010529
Filing Date
2025-05-15
Accepted
2025-05-15 08:10:35
Documents
75
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1623918
2 ex31-1.htm EX-31.1 17758
3 ex31-2.htm EX-31.2 18558
4 ex32-1.htm EX-32.1 11464
  Complete submission text file 0001641172-25-010529.txt   8343865

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE evfm-20250331.xsd EX-101.SCH 58685
6 XBRL CALCULATION FILE evfm-20250331_cal.xml EX-101.CAL 69826
7 XBRL DEFINITION FILE evfm-20250331_def.xml EX-101.DEF 289452
8 XBRL LABEL FILE evfm-20250331_lab.xml EX-101.LAB 449760
9 XBRL PRESENTATION FILE evfm-20250331_pre.xml EX-101.PRE 375538
77 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1468372
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

EIN.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36754 | Film No.: 25948846
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)